Kintara Therapeutics Inc (NASDAQ:KTRA)
North American company
Share Price Chart
- Chart currently unavailable -
Market Info - KTRA
- Market Open Price0.00
- Previous Close0.00
- Volume-
- 52w Low/High-
- Last Trade Price0.00
- Bid/Ask Price0.00
Company Info - KTRA
- Market Cap$40.940m
- SymbolNASDAQ:KTRA
- IndustryHealthcare
- SectorBiotechnology
- Currency
- ISINUS49720K1016
Company Profile
Kintara Therapeutics Inc is engaged in the development of novel cancer therapies for patients with unmet medical needs. The company is developing two late-stage, Phase 3-ready therapeutics for clear unmet medical needs with reduced risk development programs. The two programs are VAL-083 for GBM and REM-001 for CMBC. VAL-083 is a small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system, ovarian, and other solid tumors. The company is also advancing its proprietary late stage photodynamic therapy (PDT) platform that holds promise as a localized cutaneous or visceral tumor treatment as well as in other potential indications.DelMar Pharmaceuticals Inc is a clinical stage drug development company. It is engaged in research and development of cancer indications.
Latest KTRA news
Currently there for this company. Visit our news hub for other news .